{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-013369","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2026-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.785660+00:00","generated_at":"2026-05-15T03:53:05.259956+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eton Pharmaceuticals initiates ET-700 pilot study for Wilson disease","bullets":["First patient dosed in double-blinded, placebo-controlled trial comparing ET-700 to Galzin and placebo.","Study uses 64Cu PET imaging to assess intestinal copper absorption in 36 healthy volunteers.","Topline results expected H2 2026; positive data could lead to pivotal study in early 2027.","CEO expects peak annual U.S. sales of ET-700 could exceed $100 million if approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-013369","json":"https://secwatch.observer/filing/0001437749-26-013369.json","markdown":"https://secwatch.observer/filing/0001437749-26-013369.md","text":"https://secwatch.observer/filing/0001437749-26-013369.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926013369/0001437749-26-013369-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926013369/eton20260401_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T03:53:05.259956+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}